NQO1 and Friedreich ataxia: Nrf2 activation increases transcription of mRNA for endogenous antioxidant enzymes such as SOD, glutathione S-transferase (GST), and NADPH: quinone oxidoreductase (NQO1), making the dysfunction of Nrf2 in FRDA a therapeutic target in FRDA.